Replay available

CareDx (NASDAQ:CDNA) Q2 2020 Earnings Call

CareDx (NASDAQ:CDNA) Q2 2020 earnings call, held 2020-08-20. Watch the replay and read the transcript on 6ix.

Thu, August 20, 2020 at 4:30 PMendedReplay
CareDx (NASDAQ:CDNA) Q2 2020 Earnings Call
Company
CareDx, Inc. (NASDAQ:CDNA)
Period
Q2 2020 earnings call
Date
Thu, Aug 20, 2020, 4:30 PM ET
Replay
Watch the replay on this page · 39 min

On 6ix: 6ix.com/event/caredx-inc-cdna-q2-2020-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Greetings. Welcome to CARE-Dx, Incorporated's second quarter 2020 earnings conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I will now turn the conference over to Greg Medachuk. Thank you. You may begin.

0:28 Good afternoon and thank you for joining us today. Earlier today, CareDx released financial results for the quarter ended June 30, 2020. The release is currently available on the company's website at www.caredx.com. Peter Mogg, Chief Executive Officer, and Michael Bell, Chief Financial Officer, will host this afternoon's call. Before we get started, I would like to remind everyone that management will be making statements during this call that include forward-looking statements within the meaning of the federal securities laws. which are made pursuant to the safe harbor provisions of the Private Securities Reform Act of 1995. Any statements contained in this call that are not statements of historical fact should be deemed to be forward-looking statements. All forward-looking statements including without limitation are examination of historical operating trends, expectations regarding coverage decisions, pricing and enrollment matters, and our future financial expectations and results are based upon current estimates and various assumptions.

1:28 The information provided in this conference call speaks only to the live broadcast today, August 4, 2020. CareDx disclaims any intention or obligation except as required by law to update or revise any information, financial projections, or other forward-looking statements, whether because of new information, future events, or otherwise. This call will also include a discussion of certain financial measures that are not calculated in accordance with generally accepted accounting principles.

2:21 Reconciliation to the most directly comparable GAAP financial measure may be found in today's earnings release filed with the FCC. I will now turn the call over to Peter.

2:32 Thanks, Greg, and good afternoon, everyone. I'm pleased to welcome you to CareDx's call to review our results for the second quarter of 2020. Back on April's call, I began by talking about how we chose Transplant Proud as our theme for 2020 and how proud I was of our team's response to the COVID crisis. Today, I can say that our team has taken CareDx to a whole new level. The dedication and resiliency of every member of Care DX is truly inspiring. I want to thank our employees and say you have made the lives of transplant patients and their caregivers better because of your grit, your hard work, and your devotion. You exemplify what essential businesses and workers stand for. Thanks for leaning in.

3:20 Now turning to our exceptional results for the quarter. In the second quarter of 2020, we reported revenue of $41.8 million, an increase of 33% compared to the second quarter of 2019. Growth primarily came from our testing services, with revenue of $36.3 million. We provided over 17,100 allosure kidney and allomap heart patient results, an increase of 44% year over year. Product revenue for the quarter was 3.3 million, and digital revenue added 2.2 million to the top line. We believe that these are exceptional results in a challenging environment. During this crisis, we have chosen to invest strategically in areas that will accelerate the building of our mode in transplant care.

4:09 We are leaning in. These strategic areas include our direct-to-patient capabilities and our clinical activities, especially those focused on our multimodality testing and digital solutions. These investments will all accelerate our precision medicine offerings in transplantation. Our digital acquisitions have proven to be a tremendous asset as it has enabled us to pivot faster than anyone in the industry in building out our offerings. Transplant Proud. In the latter part of March and throughout the second quarter, several cities experienced rapid increases in newly confirmed cases of COVID-19. With these increases came more requests from physicians and patients for remote track and mobile phlebotomy. As a result, our remote track services have experienced continued growth. For the quarter, over 40% of our patients' results originated from remote track or other mobile phlebotomy services.

5:10 Under the tremendous leadership of Red Theto, in just over four months, RemoDrac has gone from an idea, gone from conversations with clinicians to a full service offering that now originates a significant proportion of our patient results. RemoDrac has provided patients peace of mind by giving them the ability to avoid transplant centers and physician offices, thus reducing the risk of contracting COVID-19. To date, around 150 transplant centers are offering RemoTrack to their patients, and over 4,000 kidney, heart, and lung transplant patients have enrolled. Our nationwide network of mobile phlebotomists has grown to over 10,000. Not only have we had to change the way we call on customers, but the pandemic has also changed the way we communicate and present important clinical information to leaders in the field of transplantation.

6:03 In late May, at the Virtual American Transplant Congress Annual Meeting, our program included virtual abstract sessions, virtual symposia, and prominent authors delivering 10 abstracts. Cutting-edge content on AlloShore, Allomath, iVox, and KidneyCare was presented. Having 10 abstracts accepted for presentation at ATC and having over 1,000 clinicians, patients, and investors log on to our virtual sessions was exceptional. and quite an honor for our clinical team which is led by Chandra Lakia. The large turnout for our virtual events demonstrates our leadership position in transplant care as we are at the forefront of innovation in this space. Others might be talking, CareDx is doing, and the field is recognizing our efforts and our dedication.

6:51 We are also using these new tools to communicate to clinicians and patients and during industry conferences and interactions with the transplant community. We are very encouraged by the positive feedback from nephrologists, cardiologists, transplant coordinators, and patients about our virtual advisory board. We have and will continue to virtually support our customers and to call on our physician advocates and transplant center administrators to every extent possible. While we have successfully pivoted our testing services business with exceptional success, we also point out that our product business, with its many launches, has been negatively impacted by the COVID pandemic.

7:37 Hospitals and transplant laboratories across the U.S. and Europe have restricted access to their facilities for outside personnel. In May, we received CE Mark for AlloCPX17, our best-in-class solution for HLA matching. of Transplant Donors and Recipients. Despite providing better care for patients by extending the typing range to non-classical HLA loci, traction of our launch efforts will be delayed in the US and Europe due to the COVID pandemic. While our product revenue is not what we had hoped for, we had the chance to welcome exceptional talent into this group. With Paul Tausch, we added strong commercial leadership from Thermo Fisher, Paul has been leading the success of One Lambda with Dr.

8:23 Terasaki for over 25 years. Turning to our operations, we continue to adapt to a dynamic COVID environment in transplant centers, hospitals, and even within our own facilities. We have established internal operating solutions to protect our employees and their families while continuing our commitment to supporting patients. Despite COVID affecting many large cities across the United States, I'm pleased to report that we have continued our operations without interruption. We are firmly committed to our mission, and we never wavered from our commitment to prioritizing patients. With respect to our ongoing clinical studies, as one would expect, we did see a slowdown in enrollment in OCRA during the second quarter.

9:12 However, we experienced an increase in short. and utilization of heart care as many centers have switched their biopsy protocols to non-invasive surveillance. Our heart franchise has been exceptionally strong in the second quarter and the value proposition of our precision medicine solution has never been clearer. In the second quarter, we recorded our first ever allocell revenue. While it was only a small amount of revenue, it clearly demonstrates the next step in expanding our transplant technology from solid organs To pursue this, we have built an exceptional team with strong business development hires as well as elevating internal talent. While we are in the proof-of-concept phase, we have fielded many inquiries from pharmaceutical and biotech companies of all sizes. We are very excited about the opportunities in cell therapy and we will continue to update you on our progress.

10:09 Finally, turning to the balance sheet. The second quarter saw a significantly strengthened our cash position. We closed the quarter with $211 million of cash following a very successfully executed public offering in June. Mike Bell and the team have done an exceptional job. We feel we now have the right size balance sheet to continue to accelerate our revenue growth and take full advantage of opportunities available to us. Before I turn the call over to Mike, I would like to take this opportunity to thank our employees again. We are firing on all cylinders. We provide our services to more transplant patients every day. I'm very confident the best is yet to come. As you can tell, I'm optimistic about the remainder of 2020 and look forward to providing updates on the progress in future communication.

11:01 Now I'll hand over to Mike to discuss our financials. Mike. Thanks, Peter.

11:06 Turning first to the income statement, total revenue for the second quarter was $41.8 million, a year-over-year growth of 33%. Growth in revenue was primarily driven by Alishore Kidney and Alimap Heart. We saw increased penetration primarily due to the success of RemoTrack and the need for centers to be able to monitor their patients remotely. As a result, testing services revenue in the second quarter increased 41% year-over-year to $36.3 million. Our second quarter product revenue decreased to $3.3 million due to the COVID-related issues outlined earlier by Peter, and our digital revenue was $2.2 million. Moving to our gross margins, for the second quarter of 2020, the gross margin was 64% compared to a gross margin of 63% in the same period of 2019.

11:56 The non-GAAP gross margin for the quarter was 68% compared to 67% in the prior quarter. On a sequential basis, the non-gap gross margin was down approximately 300 basis points compared to the first quarter of 2020, primarily due to the increased number of tests originating from remote track or other mobile phlebotomy services. As a reminder, the cost of a mobile phlebotomy draw can be between $100 and $150 more expensive than a lab draw. Although the incremental costs of remote track and mobile blood draws are here to stay, We are still confident that gross margins will continue to improve over time due to the operating leverage of our testing lab in Brisbane. For the second quarter of 2020, net loss was 6.6 million compared to a net loss of 7.8 million in the same period of 2019.

12:48 Our net loss per share was 15 cents for the quarter compared to a net loss per share of 19 cents in the second quarter of 2019. Non-GAAP net income was $1.7 million in the second quarter of 2020, compared to a non-GAAP net loss of $0.1 million in the same period of 2019. Our non-GAAP net income per share in the second quarter of 2020 was $0.04, compared to a non-GAAP net loss per share of $0.00 in the same period of 2019. GAP and NGAP net income in the second quarter include other income of $4.8 million related to the CARES Act provider relief funding that we received in April. As a reminder, we define adjusted EBITDA as NGAP net income before interest, income tax, depreciation, amortization, and other income and expense.

13:43 For the second quarter of 2020, we recorded a negative adjusted EBITDA of $2.8 million and Thank you very much. Our G&A costs increased sequentially in the second quarter, primarily because of the higher legal expenses related to our ongoing litigation efforts.

14:29 We also booked additional employee-related expenses to reflect the remarkable performance of our employees during this highly unusual quarter. Peter had mentioned that we are leaning in and seizing opportunities to build out our moat during this crisis. We expect operating expenses to increase in the third and fourth quarters this year. We will continue to develop our pipeline and continue to focus on top-line growth. We will also expand our sales and marketing efforts beyond transplant centers by going direct to patients and to community nephrologists. In the second quarter, we significantly strengthened our cash position. In April, when the COVID crisis and uncertainty was at its peak, We utilized our at-the-market program to raise approximately $24 million.

15:17 We followed that in June with a successful public offering of approximately 4.5 million shares of common stock, raising roughly $135 million. As a result, cash-in-cash equivalents on June 30, 2020, were $211 million. And, as Peter outlined earlier, this puts us in a position of strength to execute on opportunities to build on our transplant platforms. Net operating cash flow was $24.1 million in the second quarter of 2020. This includes both the $4.8 million CARES Act provider relief funding we received in April, as well as the $20.5 million we received from CMS through its expanded, accelerated, and advanced payment program. As a reminder, we expect CMS to recoup the advanced payment between August and November this year.

16:06 Turning to guidance, whilst we have seen many transplant centers return to some level of normality Over the last couple of months, there is still much uncertainty surrounding the ongoing impact of COVID-19 on our business. And as such, we will not currently be providing revenue guidance for the full year 2020. I'll now hand back over to Peter.

16:28 Thank you, Mike. In closing, the second quarter was an exceptional quarter for KDX. With COVID-19 limiting access to hospitals and transplant centers in the United States, Our team continues to roll out solutions like RemoDRAC across the country to bring much-needed surveillance testing to transplant patients. We believe we are experiencing the beginning of a tectonic shift in the way clinicians are monitoring the health of transplant patients and precision medicine overall. The movement towards DNA and molecular testing from traditional biopsies is happening, and we are well-positioned for this shift, but importantly, we are also the reason for it. Thank you all for joining the call and I will open the call for questions.

17:16 Thank you. If you would like to ask a question, please press Star 1 on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press Star 2 if you would like to remove your question from the queue. And for participants using speaker equipment, it may be necessary to pick up your handset before pressing the Star key. Our first question is from Brandon Julliard with Jeffries. Please proceed.

17:43 Hey, thanks. Good afternoon. Peter, just on remote track, I'd be curious to just get your prognostications of where you think that program can go, the portion of volume do you think it contributes in the back half of the year, and is there some upper level where you think Thank you so much, Brandon, and greetings to Nashville. Good to have you on the phone, so thank you very much for joining. Now, remote track is

18:18 Embraced by Patients. They love it. It's an amazing service where we have phlebotomists going to the home of the patient and make sure that they get the blood draw in the convenient environment that they're used to. And so they don't have to go to transplant centers. And this has been embraced by many patients across the country. 150 centers are using the service now. Now, you know, we have 4,000 patients on the platform. That number is growing every day. But it's really depending on where transplant centers are and what their stance is towards telehealth. Some centers have really jumped in and adopted telehealth solutions. Some other centers are actually moving now back as they're reopening up to face-to-face visits. And so it's hard to say. That's one of the reasons why Mike said it's hard to give guidance yet because there's a lot of variability across the country.

19:10 But remote track as a service is here to stay. We're all in. We have invested into the platform, and there are many, many patient care managers now on CareDx that are servicing this patient population. So there is significant growth drivers going forward.

19:25 I think you talked about launching the AlloCare app later this year, maybe by September. Mike kind of mentioned some more direct-to-patient marketing programs. Are those two tied together? You know, sort of talk about what that app is, how it helps you actually capture more volumes and kind of what the span of marketing plan looks like around that initiative.

19:47 Oh, yeah. No, thank you very much. You know, this is in the broader context of QDX managing the transplant patient journey. And you hear us with RemoTrack. The reason why we were able to pivoting so quickly was having our digital solution encompassing our surveillance testing modalities. Now, you know, with AlloCare, We are prone to tackle one of the biggest issues in post-transplant care, which is compliance and adherence to a standardized protocol. And we're all about standardization so we can further individualize the offering. With AlloCare, we're now having a simple patient app that allows the patient to monitor their schedule, to be able to monitor their medications, and maybe even build a community for transplant patients. So we're very excited about this. This is another touchpoint for CareDx with a patient.

20:35 that make sure that there is a patient journey. So AlloCare is launching in September, and we're very excited about that launch.

20:49 Thank you. Our next question is from Rachel Sassnell with Piper Sandler. Please proceed.

21:02 Hi, this is Rachel. I'm with Steve today. Congrats on the nice quarter and thanks for taking the questions. So first off, can you just give us an update? Yeah. So first, can you just give us an update on the transplant pipeline and impacts on donations due to the pandemic or if you start to see that pipeline return and geographic regions is starting to open back up?

21:21 You know, I think overall transplant volume is roughly about 7% down year to date. So a very, very nice recovery because we obviously, living donations has been stopped for a few weeks. But, you know, as we look around the country right now, many transplant centers are back to normal or maybe even overcompensated because transplant centers are really at the forefront of wanting to come back and supporting. Now, you know, transplant volumes is back up and we don't see that this will further down even so we see some cities might being in hot spots of COVID because the organs will be reallocated to other parts in the country. Great, that's awesome.

22:29 So then on the OCRA and SHORE studies, so can you give us any more clarity on the timing and if enrollment has returned given those delays you saw due to COVID earlier this year?

22:39 Yeah, you know, SHORE, you know, the context of ALOMAP and ALOSHORE is kind of standard of care now. It's so well penetrated. I think CareDx has defined for many years with ALOMAP post-transplant surveillance that was non-invasive. But now in this COVID era, we have seen a tectonic shift Thank you very much. That is more driven by research coordinators and research events.

23:30 And so we have seen some research coordinator being furloughed, some research activities actually put aside in these kidney transplant centers. And so on kidney, we have seen a small delay on the OCRA recruitment. But actually, as we are reopening up the country, the last weeks have been very promising on our recruiting of our OCRA studies. I will say as well is that, you know, we had a phenomenal second quarter even without OCRA being supportive. So this really speaks testimony to the value proposition that we bring to transplant centers overall. Great. Thank you. Those are all my questions.

24:14 Thank you, Rachel. Our next question is from Alex Novack with Craig Hallam Capital Group. Please proceed.

24:23 Great. Good afternoon, everyone. In the centers that have moved from doing more allosures and allomaps during the heart of the pandemic and essentially going away from biopsy, and, you know, irregardless of if they're doing remontrac or not, has there been a durable benefit as these centers have reopened and tried to go back to normal? I guess, you know, said another way, do you think this pandemic at all has accelerated your penetration goals into some of those transplant centers?

24:50 I would say from, you know, The proof is in the budding and we'll need to see that in a couple of quarters, but absolutely. I think we have seen a true shift away from biopsy protocols into non-invasive procedures. I've talked to so many cardiologists that said we always wanted to retire our biopsy protocol and maybe now is the time to do it. Now, you know, the reality might be that some of them are going back onto biopsy. We'll see that in the past. But if you see the feedback from patients that don't have to spend more or less a day in a In a cath lab and go through an invasive procedure and now they are doing this for the blood test, you wouldn't believe how many positive patient notes I receive and the entire team receives from patients that are saying, well, this is so much more convenient and not being able to do that from home even better.

25:37 But, you know, I think there is a true shift in care, but yet to be seen, right? I mean, you know, this is one quarter and I think the heart franchise has been extremely successful, but, you know, I think this is something to stay.

25:53 That's great to hear. And of the 4,000 RemoTrack patients, how many would you say are brand new to CarityX? And just on RemoTrack in general, can you say if compliance has actually improved compared to the traditional getting a blood draw in the clinic? Because I remember that being a core piece of the RemoTrack thesis, that compliance would increase.

26:17 and Alex, you have followed the story for a long period of time, so I'm not wondering why you are asking that question. We ourselves are looking at these numbers very, very carefully. There have been a number of new patients come onto the RemoTrack franchise, and it's probably true that some patients have been pushed out for a few weeks or another quarter for their surveillance visit, but I think this is a brand new trend. I think RemoTrack has been exceptionally successful in – areas where COVID hit extremely hard, like New York, or now we're seeing some uprise in Florida, and guess what? Remote track is just accelerating. But, you know, I think we'll need to give ourselves a couple of quarters to really demonstrate how much is remote track there to stay, what is the impact on surveillance, and I think, you know, what you're getting at, what's adherence?

27:10 With CaretX now being much more Thank you very much.

27:44 Yeah, thanks, Peter. I mean, Remotrack's been an outstanding success, and I think we've obviously added new sensors, new patients, as well as adherence has gone up. And Peter has mentioned this is obviously from a four-month sort of experience that all those three parameters have been certainly seen during the period of Remotrack among the 4,000-plus patients that we've had enrolled in this program.

28:13 All right, I understand. Thanks, Rich, for that. And then the last question for me, any update on heart care reimbursement, where that sits with CMS and Meridian and Palmetto? And then when would you expect to request kidney care reimbursement?

28:29 Excellent questions. I'll give the kidney care. This is really too early yet for us to comment on. Alex will probably see this communicating about our reimbursement timelines on kidney care. Once we have clarity on heart care, and I'll punt that question over to Mike Bell on heart care.

28:46 Yeah, on heart care, Alex, I think no change from really the status last time we spoke. We're still expecting that to go to the final coverage decision towards the back end of the year. It's usually, you know, within 12 months from the public comment period, which... which was October of last year. So we're expecting something around that timing. All right. Understood. Thank you, everyone.

29:19 Alex, keep the fingers crossed for us in the third quarter, right? So thank you for doing that. Our next question is from Andrew Cooper with Raymond James. Please proceed.

29:30 Hi. Thanks for the questions. Maybe just first, I think, Peter, you mentioned it at least as potentially part of what went on in the quarter, but just do you have any sense for was there any amount of volume that might have been delayed from one cue or sort of adjusted based on Remo track becoming available that we should think about as we think about pacing kind of through the remainder of the year?

29:57 Excellent question, Andrew, and we finished, obviously, the second quarter very strong, and we see that trend continue into the third quarter. I think on the heart franchise, we are looking at our numbers and saying this has been very, very strong in the second quarter. Will that momentum carry on throughout the rest of the year? So I think that's a good question. On the kidney volume, I think the value proposition, at the end of the day, We're so low-penetrated overall, so this is such a big opportunity that we're here to stay and build the franchise going forward. So in that sense, there's so much ample opportunity. Now, we did comment on the side note as well, is that we are building out our presence in community nephrology. So there's going to be an ongoing expansion for cardiacs, tremendous fields to grow going forward. So in that sense, you know, We see continued growth going forward.

30:56 Thanks. That leads actually right into the next question I wanted to ask, which was on that community nephrology effort. When you think about that, should we think about this as building direct one-by-one in hospital settings or community settings, or is there an opportunity to maybe partner with some of the larger players that are interacting with ESRG patients and patients that presumably are coming on to transplant lists. What's the way we should think about you trying to address that?

31:30 Thank you so much, Andrew. You've been following the company as well. And we're all about the continuity of care, the transplant patient journey. We're managing patients on the wait list. We are managing them during the transplantation procedure. And then we are managing them also post-transplant. Reg Cito has actually masterminded our presence into the community nephrology setting, which is a very natural progression about growing our franchise, expanding from a transplant center now into the community nephrology setting. So it's a very, very natural evolution. Over to you, Reg.

32:03 Yeah, thanks Peter. I mean, I think, you know, it's more than 150 centers quarter on quarter actively using Allishore. We've had, you know, deep penetration within the centers and now we're, you know, three years on we have patients, you know, moving community year two and year three and obviously year post year one. So, with that in mind, we've been able to, you know, develop a plan which allows us to now strategically follow these patients and also bring new patients into the world of Allishore. So, that's something that We have a team that's being built out to allow for that expansion as far as that cost is.

32:40 Great. I'll stop there. I appreciate the question. Our next question is from Yi Chen with H.P. Wainwright. Please proceed.

32:55 Thank you for taking my questions. Could you please comment on the transplant volume in second quarter and early third quarter as compared to those in prior periods? And do you think the transplant volume will continue to go up during the remainder of 2020 or remain at current levels for an extended period of time due to the new COVID-19 cases in the country?

33:19 Excellent question. You know, I think this is really driven by two dynamics. One is living organ donation is back to a previous level, and deceased owner donation has actually never stopped. So in a way, your question is about will living organ donation continue to increase, and I would say yes. I think there was a shell shock reaction in many transplant centers during COVID-19 that said, oh, we're backing off. And now as they have learned how to deal with the crisis, we see actually a significant increase. The latest numbers on organ availability, these are actually significantly increasing due to COVID-19 because of cardiovascular death and, believe it or not, because of overdosing. There's a lot more patients, unfortunately, that are overdosing and there are more patients that are sedentary at home that are experiencing cardiovascular death, which leads to an increase in organ availability with the increasing need of Organ Transplantation, because we have 100,000 patients on the waiting list on kidney.

34:22 So in a way, I see a significant increase, which is also driven by a support of kidney health initiative from CMS, which you might have read last year, that we're kind of releasing the one-year graft survival metric as the key quality metric for transplantation. And releasing that metric really allows transplant centers to do Take a little bit more risk when we are transplanting and not only taking perfect kidneys, but also taking kidneys that are okay. And that will drive volume. And the last thing that I would say, Yichen, is that many of these centers are also financially driven institutions and transplantation is a profitable activity within a hospital. And as we read now, many hospitals are looking for sources of income Transplantation might be an easy area to be because you have relatively low case rates, but these tend to be pretty profitable.

35:21 So I think all these things will play to a significant increase in transplantation throughout the rest of the year.

35:29 Got it. Thanks. My next question is related to operating expenses, which have increased in second quarter. Thank you very much.

36:07 You have seen us as a company being extremely responsible and extremely focused on building a long-term sustainable business model. But this was the quarter where we said, no, we're going, you know, other companies might go another way, but we are going all in. And so I'll turn over to Mike, which can give you more detail.

36:29 Yeah, I think on the remote track side, Most of the impact that we saw actually was in the cost of goods line and impacting our gross margin. On the call earlier, I talked about a 300 basis point impact from remote track on the gross margin. And so we'll probably see those costs are here to stay, and we'll see them going forward. On the OPEC side, there was cost. Thank you very much. COVID-related, as we saw more expense related to shore and more uptake of hot car. But some of those costs were non-related to COVID. We had this upfront to Cornell, so that's for developing the pipeline, and that was for Euromap. And on the G&A line, we also had some increase in our legal expense line. But, yeah, I mean, overall, as Peter mentioned, I think going forward, we see a bit of a change in the business model.

37:51 and that will drive some additional expense, but again, it's all focused on top line growth. Thank you.

38:01 Thank you, Yuchen. We have reached the end of our question and answer session. I would like to turn the call back over to Peter for closing comments.

38:11 Well, thank you very much for your interest in CareDx. We will continue to keep you updated as we are going into the second half of 2020. and looking forward to keep in touch with you. Thank you so much. Bye-bye now. Thank you. This concludes today's conference. You may disconnect your lines at this time and have a pleasant evening.

Follow CareDx, Inc. into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Greg Medachuk

Investor Relations

Peter Mogg

Chief Executive Officer

Michael Bell

Chief Financial Officer

Brandon Julliard

Analyst, Jefferies

Rachel Sassnell

Analyst, Piper Sandler

Alex Novack

Analyst, Craig Hallum Capital Group

Reg Cito

SVP, Commercial Operations

Andrew Cooper

Analyst, Raymond James

Yi Chen

Analyst, H.P. Wainwright

More from CareDx, Inc.